RxDoctor Payments Data

Nicholas Genrich, APRN

Nurse Practitioner · Lincoln, NENPI 1124645072

Payments from drug & device makers

$3,417in general payments, 2019–2025

Across 148 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$839
  • Grifols USA, LLC$453
  • Boehringer Ingelheim$283
  • Harmony Biosciences LLC$274
  • Sanofi$222
  • Inspire Medical Systems, Inc.$221
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,26896%
  • Education$1494%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,417 in reported general payments places this provider in the 90th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$66,713
Medicare patients
537
Services billed
704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter167$133,119
Breztri AerosphereBudesonide/Glycopyr/Formoterol94$60,799
Stiolto RespimatTiotropium Br/Olodaterol Hcl105$58,325
Breo ElliptaFluticasone/Vilanterol34$22,533
Spiriva RespimatTiotropium Bromide33$20,658
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$13,028
Bevespi AerosphereGlycopyrrolate/Formoterol Fum24$10,528
Combivent RespimatIpratropium/Albuterol Sulfate17$8,938
Roflumilast69$6,849
Advair HfaFluticasone Propion/Salmeterol20$5,872
Varenicline Tartrate19$5,820
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,497
SymbicortBudesonide/Formoterol Fumarate16$5,385
Wixela InhubFluticasone Propion/Salmeterol17$3,191
Albuterol Sulfate HfaAlbuterol Sulfate136$2,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$50$168,680225 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$283$87,920155 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$839$76,711134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →